{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:11:57Z","timestamp":1743340317659},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,27]]},"DOI":"10.7759\/cureus.51184","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T20:25:13Z","timestamp":1703708713000},"source":"Crossref","is-referenced-by-count":2,"title":["Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient"],"prefix":"10.7759","author":[{"given":"Rakahn","family":"Haddadin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Aboujamra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homayon","family":"Iraninezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa P","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021, 12:514-23. 10.4239\/wjd.v12.i5.514","journal-title":"World J Diabetes"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya KK","year":"2020","unstructured":"Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020, 6:40. 10.1038\/s41572-020-0165-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","article-title":"Diabetic ketoacidosis: evaluation and treatment","volume":"1","author":"Westerberg DP","year":"2013","unstructured":"Westerberg DP. Diabetic ketoacidosis: evaluation and treatment. Am Fam Physician. 2013, 1:337-46.","journal-title":"Am Fam Physician"},{"key":"ref4","article-title":"Euglycemic diabetic ketoacidosis","author":"Plewa MC","year":"2023","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. StatPearls [Internet]. StatPearls Publishing , Treasure Island (FL); 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski L","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019, 63:9-14. 10.1016\/j.ejim.2019.03.014","journal-title":"Eur J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9916","article-title":"Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association","volume":"29","author":"Kitabchi AE","year":"2006","unstructured":"Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006, 29:2739-48. 10.2337\/dc06-9916","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102658","article-title":"A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care","volume":"16","author":"Taverner S","year":"2022","unstructured":"Taverner S, Eng C, Watson R, George S, Edwards A, Williams DM, Stephens JW. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care. Diabetes Metab Syndr. 2022, 16:102658. 10.1016\/j.dsx.2022.102658","journal-title":"Diabetes Metab Syndr"},{"key":"ref9","unstructured":"FDA. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. (2015). Accessed. October 28, 2019: https:\/\/wayback.archive-it.org\/7993\/20170112031553\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm."},{"key":"ref10","unstructured":"FDA. FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2015). Accessed: October 28, 2019: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibit...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition--a novel strategy for diabetes treatment","volume":"9","author":"Chao EC","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010, 9:551-9. 10.1038\/nrd3180","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani MA","year":"2015","unstructured":"Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015, 309:F889-900. 10.1152\/ajprenal.00267.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang KM","year":"2020","unstructured":"Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020, 2:218-21. 10.1016\/j.xkme.2019.12.006","journal-title":"Kidney Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for\u00a0euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry RJ","year":"2019","unstructured":"Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, Shulman GI. Dehydration and insulinopenia are necessary and sufficient for\u00a0euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019, 10:548. 10.1038\/s41467-019-08466-w","journal-title":"Nat Commun"},{"key":"ref15","article-title":"Euglycemic diabetic ketoacidosis due to gastroparesis, a local experience","volume":"112","author":"Legaspi R","year":"2015","unstructured":"Legaspi R, Narciso P. Euglycemic diabetic ketoacidosis due to gastroparesis, a local experience. J Ark Med Soc. 2015, 112:62-3.","journal-title":"J Ark Med Soc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00569937","article-title":"Euglycaemic diabetic ketoacidosis: does it exist?","volume":"30","author":"Jenkins D","year":"1993","unstructured":"Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis: does it exist?. Acta Diabetol. 1993, 30:251-3. 10.1007\/BF00569937","journal-title":"Acta Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci A","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, et al.. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014, 124:509-14. 10.1172\/JCI70704","journal-title":"J Clin Invest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.5.387","article-title":"Role of glucagon in enhancing ketone body production in ketotic diabetic man","volume":"32","author":"Keller U","year":"1983","unstructured":"Keller U, Schnell H, Sonnenberg GE, Gerber PP, Stauffacher W. Role of glucagon in enhancing ketone body production in ketotic diabetic man. Diabetes. 1983, 32:387-91. 10.2337\/diab.32.5.387","journal-title":"Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/214804-sodium-glucose-cotransporter-2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-in-a-type-2-diabetic-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:21Z","timestamp":1707509541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/214804-sodium-glucose-cotransporter-2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-in-a-type-2-diabetic-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.51184","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}